Premarket Decliner
APVO Aptevo Therapeutics6.74+0.34+5.2%
Premarket:5.37-1.37 (-20.3%)
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
ACCESS NewswireTue, 10-Mar 8:05 AM
APVO Aptevo Therapeutics5.13+2.31+81.9%
Premarket:4.45-0.68 (-13.3%)
Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
ACCESS NewswireFri, 20-Jun 8:55 AM
